Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Jonathan Pan, MD, Sushil Ghimire, MD, Tingting Zhan, PhD, Onder Alpdogan, MD, Andrew E. Chapman, DO, Matthew Carabasi, MD, Ubaldo Martinez-Outschoorn, MD, Lewis J. Rose, MD, Michael Ramirez, MD, John L Wagner, MD, Barbara Pro, MD, Mark A. Weiss, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD

Blood (2019) 134 (Supplement_1): 5318.

https://doi.org/10.1182/blood-2019-125836

Published: 2019

Journal Articles

Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells.

Renier J. Brentjens, MD, PhD, Daniel Hollyman, PhD, Jae Park, MD, Elmer Santos, MD, PhD, Raymond Yeh, Ph.D., Jolanta Stefanski, Clare Taylor, PhD, Mark A. Weiss, MD, Daniel Filippa, MD, Isabelle Riviere, PhD, Michel W Sadelain, MD, PhD

Blood (2009) 114 (22): 3436.

https://doi.org/10.1182/blood.V114.22.3436.3436

Published: 2009

Journal Articles

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Todd Rosenblat, MD, MS, Michael R. McDevitt, PhD, Deborah A. Mulford, MD, Neeta Pandit-Taskar, MD, Mark A. Weiss, MD, Mark L. Heaney, MD, PhD, Suzanne Chanel, RN, Alfred Morgenstern, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD

Blood (2008) 112 (11): 2983.

https://doi.org/10.1182/blood.V112.11.2983.2983

Published: 2008

Journal Articles

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone (PCRM): A New Highly Active Regimen for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with PCR or FCR.

Nicole Lamanna, MD, Mark L. Heaney, MD, PhD, Renier J. Brentjens, MD, PhD, Joseph G. Jurcic, MD, Mark A. Weiss, MD

Blood (2007) 110 (11): 3115.

https://doi.org/10.1182/blood.V110.11.3115.3115

Published: 2007

Journal Articles

High Level T Cell Suppression Following Purine Analog Therapy for Patients with CLL Correlates with Important Clinical Benefit.

Heather Landau, MD, Nicole Lamanna, MD, Sarah Hobart, Mark A. Weiss, MD

Blood (2006) 108 (11): 2784.

https://doi.org/10.1182/blood.V108.11.2784.2784

Published: 2006

Journal Articles

In adult ALL, less is now more

Mark A Weiss, Nicole Lamanna

Blood (2006) 107 (3): 852–853.

https://doi.org/10.1182/blood-2005-11-4606

Published: 2006

Journal Articles

Induction with Combined Modality Therapy Followed by Immunomodulated Post Remission Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML).

Seema Gupta, MD, Mark A. Weiss, MD, Joseph G. Jurcic, MD, Suzanne Chanel, RN, Bri-Anne Wilson, BA, Emily Biederman, BA, Ellin Berman, MD, David A. Scheinberg, MD, PhD, Peter G. Maslak, MD

Blood (2005) 106 (11): 2802.

https://doi.org/10.1182/blood.V106.11.2802.2802

Published: 2005

Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Has Comparable Activity but Appears To Be Better Tolerated Than Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Nicole Lamanna, MD, Matt Kalaycio, MD, Peter Maslak, MD, Mark L. Heaney, MD, PhD, Renier Brentjens, MD, PhD, Joseph Jurcic, MD, Emily Biederman, Alison N. Gencarelli, RN, Katherine S. Panageas, PhD, David A. Scheinberg, MD, PhD, Mark A. Weiss, MD

Blood (2005) 106 (11): 2127.

https://doi.org/10.1182/blood.V106.11.2127.2127

Published: 2005

Journal Articles

Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia.

James Woodworth, Ph.D., Bryan R. Leigh, M.D., Susan O’Brien, M.D., Ian Flinn, M.D., Thomas J. Kipps, M.D., Mark A. Weiss, M.D., Kanti Rai, M.D., Aron Thall, Ph.D., Dee Wynne, R.N., John C. Byrd, M.D.

Blood (2004) 104 (11): 4831.

https://doi.org/10.1182/blood.V104.11.4831.4831

Published: 2004

Journal Articles

Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia.

John C. Byrd, M.D., Susan O’Brien, M.D., Ian Flinn, M.D., Thomas J. Kipps, M.D., Mark A. Weiss, M.D., Kanti Rai, M.D., Thomas S. Lin, M.D., Jennifer Reid, M.S., Dee Wynne, R.N., Bryan R. Leigh, M.D.

Blood (2004) 104 (11): 2503.

https://doi.org/10.1182/blood.V104.11.2503.2503

Published: 2004

Journal Articles

Sequential Therapy with Cytarabine and Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).

Deborah A. Mulford, M.D., Neeta Pandit-Taskar, M.D., Michael R. McDevitt, Ph.D., Ronald D. Finn, Ph.D., Mark A. Weiss, M.D., Christos Apostolidis, Ph.D., Alfred Morgenstern, Ph.D., Chaitanya R. Divgi, M.D., Steven M. Larson, Ph.D., David A. Scheinberg, M.D., Ph.D., Joseph G. Jurcic, M.D.

Blood (2004) 104 (11): 1790.

https://doi.org/10.1182/blood.V104.11.1790.1790

Published: 2004

Journal Articles

Pentostatin and Cyclophosphamide with or without Rituximab Has Significant Activity in Patients with Previously Treated Chronic Lymphocytic Leukemia and Other Low Grade Lymphoid Neoplasms.

Nicole Lamanna, MD, Matt Kalaycio, MD, Peter Maslak, MD, Joseph Jurcic, MD, David A. Scheinberg, MD, PhD, Alison N. Gencarelli, RN, Denise Horgan, Mark A. Weiss, MD

Blood (2004) 104 (11): 3484.

https://doi.org/10.1182/blood.V104.11.3484.3484

Published: 2004

Journal Articles

Hyper-CVADinib for Ph + ALL

Mark A. Weiss

Blood (2004) 103 (12): 4377.

https://doi.org/10.1182/blood-2004-04-1284

Published: 2004

NARROW

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells.

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone (PCRM): A New Highly Active Regimen for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with PCR or FCR.

High Level T Cell Suppression Following Purine Analog Therapy for Patients with CLL Correlates with Important Clinical Benefit.

In adult ALL, less is now more

Induction with Combined Modality Therapy Followed by Immunomodulated Post Remission Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML).

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Has Comparable Activity but Appears To Be Better Tolerated Than Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia.

Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia.

Sequential Therapy with Cytarabine and Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).

Pentostatin and Cyclophosphamide with or without Rituximab Has Significant Activity in Patients with Previously Treated Chronic Lymphocytic Leukemia and Other Low Grade Lymphoid Neoplasms.

Hyper-CVADinib for Ph + ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only